A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 346
- 试验地点
- 28
- 主要终点
- Chronic GVHD-free, Relapse-free Survival (CRFS) Probability
研究概览
简要总结
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.
详细描述
Chronic Graft-versus-Host Disease (GVHD) is a complication that affects many hematopoietic stem cell transplant (HSCT) survivors; it occurs when the new cells from a transplant attack the recipient's body. The current standard GVHD prophylaxis regimen for patients with hematologic malignancies undergoing HSCT involves a combination of immunosuppressive agents given for the first 6 months after transplant. Often, patients develop GVHD and continue on these agents for much longer periods. The combination of calcineurin inhibitors (tacrolimus and cyclosporine A) with methotrexate (MTX) is the most common GVHD prophylaxis used worldwide in the context of myeloablative conditioning transplants. This regimen demonstrates better control of acute GVHD, but is less effective against chronic GVHD. Management of chronic GVHD remains a challenge and it has become a significant health problem in transplant survivors with more frequent use of mobilized peripheral blood stem cells. Additionally, several issues arise with the standard approach including various toxicity symptoms and side effects, increased risk of thrombotic microangiopathy due to CNI, no prevention of other infectious diseases, and no prevention for disease relapse.
This standard strategy of Tac/MTX will be used as a control in comparison to two other treatment plans both utilizing CNI-free methods: CD34 selected T-cell depletion in peripheral blood stem cell (PBSC) grafts, and infusion of bone marrow (BM) grafts followed by post-transplant Cyclophosphamide (PTCy). Study participants will be randomized to one of these three treatment arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged ≥ 1.0 year and < 66.0 years
- •Patients with acute leukemia in morphologic complete remission with or without hematologic recovery or with myelodysplasia (MDS) with no circulating blasts and with less than 5% blasts in the bone marrow. Patients with CMML must have a WBC count ≤ 10,000 cells/µL and < 5% blasts in the marrow. Patients with ≥ 5% blasts due to a regenerating marrow must contact the protocol chairs for review.
- •Planned myeloablative conditioning regimen
- •Patients must have a related or unrelated donor as follows:
- •Related donor must be an 8/8 match for human leukocyte antigen (HLA)-A, -B, and -C at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing. Pediatric related donors must weigh ≥ 25.0 kg., must have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter, must be willing to (1) donate bone marrow and (2) receive G-CSF followed by donation of peripheral blood stem cells (product to be determined by randomization post enrollment) and must meet institutional criteria for donation.
- •Unrelated donor must be an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be medically eligible to donate according to National Marrow Donor Program (NMDP) (or equivalent donor search organization) criteria. At time of enrollment, the donor should not have any known preferences or contraindications to donate bone marrow or peripheral blood stem cells. (Selection of unrelated donors is to be performed according to institutional practice. It is recommended that the time from collection to initiation of the cell processing be considered when prioritizing donors, as data shows better results for CD34 selection when cell processing begins within 36 hours of the end of collection)
- •Cardiac function: Ejection fraction at rest ≥ 45.0% or shortening fraction of ≥ 27.0% by echocardiogram or radionuclide scan (MUGA).
- •Estimated creatinine clearance (for patients > 12 years) greater than 50.0 mL/minute (using the Cockcroft-Gault formula and actual body weight); for pediatric patients (> 1 year to 12 years), Glomerular Filtration Rate (GFR) estimated by the updated Schwartz formula ≥ 90.0 mL/min/1.73 m^
- •If the estimated creatinine clearance is < 90 mL/min/1.73 m^2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 70.0 mL/min/1.73 m^
- •Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ≥ 50% (adjusted for hemoglobin), and forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) ≥ 50%; for children who are unable to perform for Pulmonary Function Tests (PFTs) due to age or developmental ability, there must be no evidence of dyspnea and no need for supplemental oxygen, as evidenced by O2 saturation ≥ 92% on room air.
- •Liver function: total bilirubin < 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and alanine aminotransferase (ALT) / aspartate aminotransferase (AST) < 2.5x the upper limit of normal.
- •Signed informed consent.
排除标准
- •Prior autologous or allogeneic hematopoietic stem cell transplant
- •Karnofsky or Lansky Performance Score < 70%
- •Active central nervous system (CNS) involvement by malignant cells
- •Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment
- •Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
- •Patients seropositive for HIV-1 or -2
- •Patients seropositive for Human T-Lymphotrophic Virus (HTLV)-I or -II
- •Patients with active Hepatitis B or C viral replication by polymerase chain reaction (PCR)
- •Documented allergy to iron dextran or murine proteins
- •Women who are pregnant (positive serum or urine βHCG) or breastfeeding
- •Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use 2 effective forms of birth control or abstinence for one year after transplantation
- •History of uncontrolled autoimmune disease or on active treatment
- •Patients with prior malignancies, except resected non-melanoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs.
- •Patient unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests
- •Planned post-transplant maintenance therapy except for FLT3 inhibitors or TKIs must be declared prior to randomization.
- •If it is known prior to enrollment that the hematopoietic stem cell product will need to be cryopreserved, the patient should not be enrolled.
- •German centers only: Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or participation in any other interventional clinical study.
研究组 & 干预措施
Tacrolimus/Methotrexate Control Arm
Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.
Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice.
干预措施: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate (Procedure)
Tacrolimus/Methotrexate Control Arm
Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.
Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice.
干预措施: Tacrolimus (Drug)
Tacrolimus/Methotrexate Control Arm
Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.
Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice.
干预措施: Methotrexate (Drug)
CD34 Selection Arm
Mobilized CD34-selected Peripheral Blood Stem Cell graft
Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.
Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).
Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products.
干预措施: Mobilized CD34-selected Peripheral Blood Stem Cell graft (Procedure)
Post Transplant Cyclophosphamide
Unmanipulated Bone Marrow Graft with Cyclophosphamide
干预措施: Unmanipulated Bone Marrow Graft with Cyclophosphamide (Procedure)
Post Transplant Cyclophosphamide
Unmanipulated Bone Marrow Graft with Cyclophosphamide
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Chronic GVHD-free, Relapse-free Survival (CRFS) Probability
时间窗: 2 years
The primary endpoint of the trial is Chronic GVHD/Relapse-Free Survival (CRFS), treated as a time to event variable. An event for this time to event outcome is defined as moderate to severe chronic GVHD, disease relapse, or death by any cause. Participant will be censored if lost to follow up prior to 2 years. Time is from randomization to the event of moderate to severe chronic GVHD, disease relapse, death, last follow up, or 2 years, whichever comes first. The primary analysis is performed using the intent-to-treat principle (ITT) so that all randomized patients are included in the analysis.
次要结局
- Health-Related Quality of Life (HQL) - PedsQL(Baseline, Day 100, Day 180, 1 year, 2 years)
- Percentage of Participants With Overall Survival (OS)(2 Years)
- Percentage of Participants With Treatment-related Mortality(2 Years)
- Participants With Immunosuppression-free Survival(1 Year)
- Percentage of Participants With Relapse-free Survival(2 Years)
- Percentage of Participants With Secondary Graft Failure(2 Years)
- Percentage of Participants With Acute GVHD(Day 100)
- Participants With Maximum Acute GVHD(Day 100)
- Percentage of Participants With Disease Relapse(2 Years)
- Percentage of Participants With Neutrophil Engraftment(Day 28)
- Percentage of Participants With Platelet Recovery(Day 60)
- Participants With Primary Graft Failure(Day 28)
- Percentage of Participants With Chronic GVHD(2 Years)
- Percentage of Participants With Chronic GVHD-free Survival(2 Years)
- Participants With Grade ≥ 3 Toxicity(2 Years)
- Participants Infected Post Transplant(2 Years)
- Incidence of Infections(2 years)
- Health-Related Quality of Life (HQL) - Medical Outcomes Study Short Form 36 (SF36)(Baseline, Day 100, Day 180, 1 year, 2 years)
- Health-Related Quality of Life (HQL) - Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)(Baseline, Day 100, Day 180, 1 year, 2 years)
- Health-Related Quality of Life (HQL) - MDASI(Baseline, Day 100, Day 180, 1 year, 2 years)